Lupin announces the approval and launch of Brivaracetam Oral Solution in the United States

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is the bioequivalent to Briviact® Oral Solution, 10 mg/mL, of UCB, Inc. and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the United States.

Brivaracetam Oral Solution (RLD Briviact) had an estimated annual sale of USD 135 million in the U.S. (IQVIA MAT December 2025).

Shares of Lupin Limited was last trading in BSE at Rs. 2251.10 as compared to the previous close of Rs. 2245.10. The total number of shares traded during the day was 19895 in over 1979 trades.

The stock hit an intraday high of Rs. 2259.85 and intraday low of 2235.10. The net turnover during the day was Rs. 44694922.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Approval BrivaracetamOralSolution USALaunch